Curcumin in Critically Ill Patients With Sepsis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, double-blind, placebo-controlled trial in critically ill adults with sepsis. Participants receive curcumin or placebo while continuing standard sepsis care. The study aims to determine if curcumin’s anti-inflammatory and immunomodulatory effects can improve outcomes. Eligible patients are adults with sepsis who are receiving enteral nutrition and have consent from the patient or a legal representative. The trial is conducted at a single center in Guadalajara, with collaboration from a university partner.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients older than 18 years of either sex.
* Critically ill patients with a diagnosis of sepsis admitted to the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde."
* Patients receiving enteral nutrition.
* Written informed consent signed by the patient or their legally authorized representative.

Exclusion Criteria:

* Patients with a history of allergy or hypersensitivity to curcumin.
* Patients with autoimmune diseases or severe immunosuppression.
* Patients in a terminal condition with a life expectancy of less than 48 hours.
* Patients with intolerance to enteral feeding, intestinal ischemia, intestinal obstruction, pancreatitis or short bowel syndrome.
* Patients with acute liver failure or decompensated liver cirrhosis.
* Patients with clinically significant active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage, etc.).
* Patients requiring therapeutic anticoagulation (warfarin, direct oral anticoagulants \[DOACs\], or full-dose heparin).
* Patients receiving exclusively parenteral nutrition.
* Pregnant or breastfeeding women.

Where it's running

• Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
  Guadalajara, Jalisco, Mexico Recruiting

Study contacts

• Study coordinator: Kevin S Herrmann-Villatoro, Doctor of Medicine (MD)
• Email: kherrmannv99@gmail.com
• Phone: +52 322 120 9720

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care

  This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07922213

• Early detection of sepsis-related blood clotting problems in severe burn patients

  This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.

  Recruiting Center for Traumatology and Major Burns, Ben Arous · Tunis · NCT07914205

• Neutrophil EMR3 as a biomarker for sepsis in ICU patients

  Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07896018

• Thymalfasin added to standard care for adults with sepsis and immune dysfunction

  This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07866118

• Multicenter group study of sepsis and ARDS in China

  This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.

  Recruiting at 24 sites Shanghai Zhongshan Hospital · Xiamen, Fujian and 23 other locations · NCT07863908

• Non-invasive hemodynamic guidance for sepsis care on medical wards

  This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.

  Recruiting at 2 sites Regione del Veneto - AULSS n. 7 Pedemontana · Pisa, Pisa and 1 other locations · NCT07863323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.